TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01085617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study: NCT00121264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Correlative studies
Study: NCT00857402

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peanuts
Description: 30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Daboqolo
Description: 30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
Study: NCT04686123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Stretching or Self-stretching exercises
Description: Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Stretching or Self-stretching exercises
Description: Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active strengthening Or Self-Strengthening exercises
Description: Lower trapezius muscle was strengthened under the supervision of a physiotherapist as follows: -2 sets of 5-rep./session/day, for 5 consecutive days in 1st week, progressed to 10 and 20 reps./session/day for 2 weeks and 3 weeks respectively.
Study: NCT00365144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT00116168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 0.3 mg/kg
Description: MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 1 mg/kg
Description: MEDI-528 (1 mg/kg) administered as a single, SC dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 3 mg/kg
Description: MEDI-528 (3 mg/kg) administered as a single, SC dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 9 mg/kg
Description: MEDI-528 (9 mg/kg) administered as a single, SC dose
Study: NCT01545453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab
Description: subcutaneous dose every 4 weeks
Study: NCT02980900

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post exercise protein-polyphenol supplement
Description: Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post exercise protein-polyphenol supplement
Description: Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Post exercise placebo supplement
Description: Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
Study: NCT02319057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 IR
Description: Immediate release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 IR
Description: Immediate release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 IR
Description: Immediate release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 IR
Description: Immediate release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 IR
Description: Immediate release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 IR
Description: Immediate release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR B
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR B
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR B
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR B
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR B
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR B
Description: Modified release formulation of ORM-12741
Study: NCT04624594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Feedback
Description: AI mobile application provides feedback to participants randomized to artificial intelligence group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapist Feedback
Description: PT provides feedback to participants randomized to physical therapist group.
Study: NCT00006124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02254109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR - rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04072003

Intervention type: DEVICE
Intervention: intravascular ultrasound (IVUS)
Description: use IVUS in the procedure

Intervention type: OTHER
Intervention: coronary angiography
Description: Coronary angiography is required for all PCI procedure.

Intervention type: OTHER
Intervention: coronary angiography
Description: Coronary angiography is required for all PCI procedure.
Study: NCT01566851

Intervention type: OTHER
Intervention: Cardiovascular check-up
Description: Cardiovascular check-up once a year in patients with rheumatoid arthritis
Study: NCT00593827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m\^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
Study: NCT04302935

Intervention type: OTHER
Intervention: Global pain-assessment
Description: Global pain-assessment, based on the ICF framework
Study: NCT04254809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-Evaluating Suicidal Thoughts
Description: Re-Evaluating Suicidal Thoughts (REST) is a is a computerized intervention designed to mitigate the experiential avoidance of suicidal thoughts. Over the course of approximately 30 minutes, individuals are provided with psychoeducation regarding the incidence rate, origin, conceptualization, and misconceptions of suicidal thoughts. Empirical evidence is presented to provide a scientific understanding of suicidal thoughts, and is aided through the use of metaphors to make concepts more accessible to viewers. REST draws from therapeutic strategies rooted in cognitive behavioral therapy (CBT) and Acceptance and Commitment Therapy (ACT) to further suggest tips for accepting (cp. approving of) the occurrence of suicidal thoughts, and introduces mindfulness and acceptance strategies for coping with them.
Study: NCT01085617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate
Study: NCT02980900

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post exercise placebo supplement
Description: Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre bed protein-polyphenol supplement
Description: Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre bed protein-polyphenol supplement
Description: Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pre bed placebo supplement
Description: Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre bed placebo supplement
Description: Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
Study: NCT02579057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection Solution (SCP-101)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection Solution, USP
Study: NCT03373669

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cholera Vaccine
Description: Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi. Shanchol requires no oral buffer for administration, is approved for persons greater than 1 year of age, and requires 2 doses at two-week intervals. It became World Health Organization (WHO) prequalified in 2011.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjusted Dose Oral Cholera Vaccine
Description: The Adjusted Dose Oral Cholera Vaccine is given in two doses, with the second dose given at six months, rather than the manufacturer described 2 week interval between first and second dose.
Study: NCT02624687

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No contact control
Study: NCT01545453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab
Description: subcutaneous dose every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab
Description: subcutaneous dose every 4 weeks
Study: NCT04475380

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: PCI for treatment of coronary or bypass graft lesions
Study: NCT04642209

Intervention type: DEVICE
Intervention: Aggregometry
Description: After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test.~If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia.~If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS \<4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation.
Study: NCT04072939

Intervention type: OTHER
Intervention: Patients having had a lens surgery
Description: Dilated fundus exam
Study: NCT00552279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix TM
Description: Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervarix TM
Description: Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
Study: NCT04211948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic surgery
Description: Pancreatectomy with robotic assisted system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: Traditional open pancreatectomy
Study: NCT01545453

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous dose every 4 weeks
Study: NCT02169973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-MK-3168
Description: Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-MK-3168
Description: Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-MK-3168
Description: Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
Study: NCT02138422

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xilonix

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01085617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study: NCT02758756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
Study: NCT03543618

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sloped
Description: Placement of implant with sloped design

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Placement of implant with conventional design
Study: NCT02593201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended antibiotics (cefazolin or ceftazidime)
Description: To continue with the existing effective antibiotic therapy for one extra week

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Usual antibiotics (cefazolin or ceftazidime)
Description: Usual duration of effective antibiotic therapy therapy
Study: NCT01200849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Label
Description: A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
Study: NCT01632137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide 2% ophthalmic suspension
Description: Instill one drop into each eye 4 times a day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Instill one drop into each eye 4 times a day for 4 weeks.
Study: NCT02824965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
Study: NCT01085617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation
Study: NCT02824965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21
Description: CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
Study: NCT00557427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypericum
Description: 250mg tablets twice daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 20mg - 40mg daily for 8 weeks
Study: NCT04019431

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein, vegetable protein or animal protein
Description: meal replacements or animal protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein, vegetable protein or animal protein
Description: meal replacements or animal protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein, vegetable protein or animal protein
Description: meal replacements or animal protein